News


All series


All News

The landscape for treatment of gynecologic cancer has changed since 2014, however, better therapeutic strategies and better biomarkers are needed in the realm of gynecologic cancers, Bradley J. Monk, MD, said during a recent webinar about meeting unmet clinical needs in cervical cancer.

Adding atezolizumab (Tecentriq) to standard carboplatin and etoposide significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone in the frontline setting, according to results from the IMpower133 study.

Adult patients with&nbsp;<em>ALK</em>-positive, locally advanced or metastatic non&ndash;small cell lung cancer who had not received a prior ALK inhibitor experienced a more than 50% reduction in the risk of&nbsp;disease progression or death with treatment with brigatinib (Alunbrig), compared with&nbsp;the first-line standard of care, crizotinib.

Duvelisib (Copiktra) has been approved by the FDA for the&nbsp;treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.&nbsp;Both indications are for the treatment of patients who have received at least 2 prior therapies.

Based on data from the phase III MURANO trial, the European Medicines Agency&rsquo;s Committee for Medicinal Products for Human Use has recommended the approval of venetoclax&nbsp;for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy. AbbVie, a co-developer of venetoclax with Roche, announced the CHMP&rsquo;s decision in a news release.

The FDA has received a new drug application for&nbsp;erdafitinib as a treatment for&nbsp;patients with locally advanced or metastatic urothelial carcinoma and <em>FGFR</em> genetic alterations whose tumors progressed following chemotherapy,&nbsp;Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor, has announced.

Novel immunotherapy combinations are currently under investigation for the treatment of patients with&nbsp;hepatocellular carcinoma, with several promising phase III trials incorporating checkpoint inhibitors now underway. Finding successful ways to combine these therapies is among the most significant trends emerging&nbsp;as part of the next wave of discovery in the field, according to experts.

According to a presentation during the 2018 International Liver Cancer Association Annual Conference, the rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded systemic treatment options over the last 2 years. This has created a need for new sequencing strategies in HCC.&nbsp;